Mevion Medical Systems has announced that its MEVION S250i proton therapy system has received approval from China’s National Medical Products Administration (NMPA), marking the first compact, integrated proton therapy system to gain clearance in the country.

The MEVION S250i combines a superconducting proton accelerator with an integrated gantry, creating a compact, energy-efficient system designed for single-room installations. It features HYPERSCAN pencil beam scanning technology, which delivers precise tumor targeting with reduced treatment times, and Adaptive Aperture pMLC technology, which minimizes damage to healthy tissue by enhancing dose delivery accuracy.

“We are thrilled to receive NMPA approval for the MEVION S250i,” said Dr. Tina Yu, CEO of Mevion Medical Systems. “This approval is a testament to our commitment to providing innovative and accessible cancer treatment solutions. We believe the advancement of the MEVION S250i will make a significant contribution to the fight against cancer in China.”

The compact design of the MEVION S250i offers several advantages over conventional proton therapy systems. Its smaller footprint facilitates integration into existing hospital infrastructure, while its cost-effectiveness broadens accessibility to patients. Faster treatment times also enhance patient comfort and clinic efficiency.

The Littleton, Massachusetts-based company plans to support the system’s rollout in China by providing training, education, and maintenance services. The approval builds on the company’s established presence in the U.S., where Mevion systems are used in over half of the country’s compact clinical proton therapy centers, including at National Cancer Institute-designated Comprehensive Cancer Centers.